We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
-2.1%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$34.1B
AUM Growth
-$2.63B
(-7.2%)
Cap. Flow
-$362M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
13.14%
Holding
2,315
New
186
Increased
813
Reduced
981
Closed
182
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan Chase
JPM
|
+$283M |
| 2 |
Medtronic
MDT
|
+$96M |
| 3 |
Philip Morris
PM
|
+$80.4M |
| 4 |
United Parcel Service
UPS
|
+$75.5M |
| 5 |
Dominion Energy
D
|
+$74.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cardinal Health
CAH
|
+$178M |
| 2 |
General Mills
GIS
|
+$158M |
| 3 |
ExxonMobil
XOM
|
+$138M |
| 4 |
ServiceNow
NOW
|
+$96M |
| 5 |
Keysight
KEYS
|
+$72.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.14% |
| 2 | Financials | 15.14% |
| 3 | Technology | 13.55% |
| 4 | Consumer Discretionary | 8.1% |
| 5 | Consumer Staples | 7.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RGLS
676
DELISTED
Regulus Therapeutics
RGLS
| $4.94M | 0.01% |
2,904,826
| – | – |
|
677
HDFC Bank
HDB
$115B
| $4.92M | 0.01% |
168,262
+9,344
| +6% | +$287K |
|
678
MacroGenics
MGNX
$258M
| $4.88M | 0.01% |
1,410,599
+303,053
| +27% | +$1.16M |
|
679
Vanda Pharmaceuticals
VNDA
$300M
| $4.88M | 0.01% |
493,845
+8,564
| +2% | +$90.4K |
|
680
News Corp Class A
NWSA
$16.2B
| $4.86M | 0.01% |
321,598
-272,034
| -46% | -$4.56M |
|
681
Celanese
CE
$5.14B
| $4.84M | 0.01% |
53,579
+128
| +0.2% | +$14.1K |
|
682
Community Health Systems
CYH
$417M
| $4.84M | 0.01% |
2,250,398
-45,379
| -2% | -$150K |
|
683
SM Energy
SM
$9.07B
| $4.76M | 0.01% |
126,477
+22,304
| +21% | +$877K |
|
684
Tetra Tech
TTEK
$9.3B
| $4.76M | 0.01% |
185,055
+51,945
| +39% | +$1.45M |
|
685
Boston Scientific
BSX
$63.6B
| $4.73M | 0.01% |
122,113
+230
| +0.2% | +$9.23K |
|
686
Radian Group
RDN
$4.63B
| $4.72M | 0.01% |
244,686
+5,779
| +2% | +$123K |
|
687
BorgWarner
BWA
$12.6B
| $4.68M | 0.01% |
169,438
+8,950
| +6% | +$289K |
|
688
Citi Trends
CTRN
$474M
| $4.68M | 0.01% |
301,789
+41,564
| +16% | +$975K |
|
689
Iridium Communications
IRDM
$4.97B
| $4.67M | 0.01% |
105,208
+82,176
| +357% | +$3.56M |
|
690
Triumph Financial Inc
TFIN
$1.5B
| $4.67M | 0.01% |
85,895
+15,177
| +21% | +$998K |
|
|
DCPH
691
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $4.59M | 0.01% |
248,166
-689,151
| -74% | -$10.8M |
|
692
Vir Biotechnology
VIR
$1.78B
| $4.59M | 0.01% |
+237,913
| New | +$6.05M |
|
693
The Joint Corp
JYNT
$121M
| $4.57M | 0.01% |
290,651
+185,177
| +176% | +$3.29M |
|
694
Vistra
VST
$47B
| $4.49M | 0.01% |
213,780
+118,343
| +124% | +$2.86M |
|
695
Vishay Intertechnology
VSH
$4.77B
| $4.46M | 0.01% |
250,718
-2,156
| -0.9% | -$42K |
|
696
ALX Oncology
ALXO
$242M
| $4.45M | 0.01% |
464,714
+7,961
| +2% | +$92.8K |
|
|
HI
697
DELISTED
Hillenbrand
HI
| $4.42M | 0.01% |
120,469
-164,961
| -58% | -$6.94M |
|
|
CADE
698
DELISTED
Cadence Bank
CADE
| $4.41M | 0.01% |
173,636
+11,494
| +7% | +$295K |
|
|
WNS
699
DELISTED
WNS Holdings
WNS
| $4.41M | 0.01% |
53,859
+127
| +0.2% | +$10.5K |
|
|
CWEN.A
700
DELISTED
Clearway Energy Class A
CWEN.A
| $4.39M | 0.01% |
150,973
-22,892
| -13% | -$777K |
|
Similar funds
Federated Hermes's Q3 2022 Portfolio in Review
As of Q3 2022, Federated Hermes held 2,315 positions worth $34.1B, down 7.2% from $36.8B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Federated Hermes's Q3 2022 filing shows 186 new, 813 increased, 981 reduced and 182 closed positions. Its largest new stake was Amylyx Pharmaceuticals: 1,329,000 shares worth $37.4M. The largest sale was Cardinal Health, an estimated $178M.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 23% a quarter earlier, followed by Financials and Technology.
- Federated Hermes's largest Q3 2022 buy was Amylyx Pharmaceuticals: 1,329,000 shares worth $37.4M.
- Federated Hermes added most to JPMorgan Chase in Q3 2022, an estimated $283M increase.
- Federated Hermes's biggest Q3 2022 reduction was Cardinal Health, cutting an estimated $178M.
- Federated Hermes fully exited Turning Point Therapeutics, Inc. Common Stock in Q3 2022, selling an estimated $69.1M.
- Federated Hermes's ten largest holdings make up 13% of its $34.1B portfolio in Q3 2022.
- Federated Hermes opened 186 new positions and closed 182 in Q3 2022.
- Federated Hermes's portfolio value fell 7.2% quarter-over-quarter to $34.1B.
Based on Federated Hermes's 13F filing for Q3 2022, filed 14 Nov 2022.